Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153403521> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2153403521 endingPage "440" @default.
- W2153403521 startingPage "432" @default.
- W2153403521 abstract "Objective. The primary objective of this study was to establish the clinic equivalence of a new Fluticasone Propionate Aqueous Nasal Spray (FANS) compared to two commercially available active treatments of fluticasone propionate nasal spray (Flonase and Flixonase ) during the mountain cedar ( Juniperus ashei ) pollen season in Texas. Material and methods. This was a multicenter, randomized, double-blind, double-dummy, active-controlled and placebo-controlled, parallel group study designed to investigate the safety and efficacy of FANS (200 mcg QD), Flonase and Flixonase (200 mcg QD) compared to placebo administered for 13 to 15 days. Patients recorded the total nasal symptoms dcores (TNSS) in a diary in the morning and evening every day. The primary endpoint was the patient-rated am and pm TNSS +1. Other key efficacy endpoints were patient-rated AM TNSS+1, patient-rated PM TNSS+1, and safety. Results. Mean TNSS values for Flonase and Flixonase were not statistically significantly different from FANS during any study day, over the entire treatment period, or at endpoint. Bioequivalence between FANS and Flonase (ratio= 0.98, 90% CI 0.91 to 1.06) as well as FANS and Flixonase (ratio=1.02, 90% CI 0.94 to 1.10) was demonstrated for the primary endpoint [Patient-Rated am and pm TNSS +1] as well as for the other key efficacy endpoints. Conclusions. The findings from this study support that FANS 200 mcg QD is therapeutically bioequivalent to both Flonase and Flixonase in the control of the symptoms of seasonal allergic rhinitis." @default.
- W2153403521 created "2016-06-24" @default.
- W2153403521 creator A5023003963 @default.
- W2153403521 creator A5056870090 @default.
- W2153403521 date "2009-12-31" @default.
- W2153403521 modified "2023-09-28" @default.
- W2153403521 title "EQUIVALENCIA CLÍNICA ENTRE EL ROCIADOR NASAL DE PROPIONATO DE FLUTICASONA GENÉRICO Y COMERCIAL EN PACIENTES CON RINITIS ALÉRGICA" @default.
- W2153403521 cites W1492724022 @default.
- W2153403521 cites W1976984814 @default.
- W2153403521 cites W1991324354 @default.
- W2153403521 cites W2002830986 @default.
- W2153403521 cites W2011058744 @default.
- W2153403521 cites W2080515725 @default.
- W2153403521 cites W2082769846 @default.
- W2153403521 cites W2097050108 @default.
- W2153403521 cites W2110978422 @default.
- W2153403521 cites W2119539558 @default.
- W2153403521 cites W2129964076 @default.
- W2153403521 cites W2132319191 @default.
- W2153403521 cites W2171803740 @default.
- W2153403521 cites W2406939847 @default.
- W2153403521 cites W2417319771 @default.
- W2153403521 cites W3192241548 @default.
- W2153403521 cites W65138352 @default.
- W2153403521 doi "https://doi.org/10.17843/rpmesp.2009.264.1404" @default.
- W2153403521 hasPublicationYear "2009" @default.
- W2153403521 type Work @default.
- W2153403521 sameAs 2153403521 @default.
- W2153403521 citedByCount "0" @default.
- W2153403521 crossrefType "journal-article" @default.
- W2153403521 hasAuthorship W2153403521A5023003963 @default.
- W2153403521 hasAuthorship W2153403521A5056870090 @default.
- W2153403521 hasConcept C112705442 @default.
- W2153403521 hasConcept C126322002 @default.
- W2153403521 hasConcept C142724271 @default.
- W2153403521 hasConcept C19720800 @default.
- W2153403521 hasConcept C203092338 @default.
- W2153403521 hasConcept C204787440 @default.
- W2153403521 hasConcept C27081682 @default.
- W2153403521 hasConcept C2776804153 @default.
- W2153403521 hasConcept C2779028295 @default.
- W2153403521 hasConcept C2780973058 @default.
- W2153403521 hasConcept C42404028 @default.
- W2153403521 hasConcept C535046627 @default.
- W2153403521 hasConcept C71924100 @default.
- W2153403521 hasConcept C85663871 @default.
- W2153403521 hasConcept C98274493 @default.
- W2153403521 hasConceptScore W2153403521C112705442 @default.
- W2153403521 hasConceptScore W2153403521C126322002 @default.
- W2153403521 hasConceptScore W2153403521C142724271 @default.
- W2153403521 hasConceptScore W2153403521C19720800 @default.
- W2153403521 hasConceptScore W2153403521C203092338 @default.
- W2153403521 hasConceptScore W2153403521C204787440 @default.
- W2153403521 hasConceptScore W2153403521C27081682 @default.
- W2153403521 hasConceptScore W2153403521C2776804153 @default.
- W2153403521 hasConceptScore W2153403521C2779028295 @default.
- W2153403521 hasConceptScore W2153403521C2780973058 @default.
- W2153403521 hasConceptScore W2153403521C42404028 @default.
- W2153403521 hasConceptScore W2153403521C535046627 @default.
- W2153403521 hasConceptScore W2153403521C71924100 @default.
- W2153403521 hasConceptScore W2153403521C85663871 @default.
- W2153403521 hasConceptScore W2153403521C98274493 @default.
- W2153403521 hasIssue "4" @default.
- W2153403521 hasLocation W21534035211 @default.
- W2153403521 hasOpenAccess W2153403521 @default.
- W2153403521 hasPrimaryLocation W21534035211 @default.
- W2153403521 hasVolume "26" @default.
- W2153403521 isParatext "false" @default.
- W2153403521 isRetracted "false" @default.
- W2153403521 magId "2153403521" @default.
- W2153403521 workType "article" @default.